Meropenem "thrive"

Meropenem, the active ingredient in Meropenem "thrive", is a carbapenem antibiotic presented as a sterile powder for reconstitution for intravenous use. It treats severe bacterial infections such as intra‑abdominal infections, urinary tract infections, pneumonia, septicemia and meningitis in hospitalized patients.

GNH USA supplies Meropenem "thrive" as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals worldwide.

Meropenem is a broad‑spectrum carbapenem used for serious bacterial infections affecting various organ systems.

- Complicated intra‑abdominal infections: provides bactericidal activity against mixed aerobic and anaerobic pathogens. - Complicated urinary tract infections: eradicates resistant Gram‑negative organisms causing pyelonephritis. - Nosocomial pneumonia: covers multidrug‑resistant strains implicated in hospital‑acquired lung infections. - Septicemia: rapidly clears bloodstream infections caused by susceptible bacteria. - Meningitis: penetrates the cerebrospinal fluid to treat bacterial meningitis caused by susceptible organisms.

Adverse reactions may occur with any intravenous antibiotic. Monitoring and supportive care are recommended.

Common Side Effects: - Nausea: mild to moderate gastrointestinal upset. - Diarrhea: may be watery and self‑limiting. - Headache: transient and usually resolves without intervention. - Rash: erythematous skin eruption. - Elevated liver enzymes: transient increase in transaminases. - Infusion site reactions: pain or phlebitis at the injection site.

Serious or Rare Side Effects: - Seizures: especially in patients with renal impairment or CNS disorders. - Clostridioides difficile colitis: severe diarrhea due to bacterial overgrowth. - Anaphylaxis: acute hypersensitivity reaction requiring immediate treatment. - Severe neutropenia: marked reduction in white blood cells. - Renal toxicity: acute kidney injury in susceptible individuals.

Use meropenem with careful clinical assessment and monitoring. - Renal function assessment: adjust dose in patients with impaired clearance. - Hepatic monitoring: observe liver enzyme levels during prolonged therapy. - Seizure risk: avoid in patients with a history of epilepsy unless benefits outweigh risks. - Hypersensitivity: discontinue if signs of allergic reaction appear. - Drug interactions: review concomitant medications for potential interactions. - Store below 25°C: keep in original packaging, protect from moisture and light.

Meropenem may interact with several agents, requiring vigilance.

Major Interactions (Avoid): - Valproic acid: meropenem can markedly reduce serum valproate levels, risking seizure breakthrough. - Other carbapenems: concurrent use may increase toxicity without added benefit. - High‑dose aminoglycosides: combined nephrotoxic potential.

Moderate Interactions (Monitor Closely): - Warfarin: may enhance anticoagulant effect, monitor INR. - Oral contraceptives: possible reduction in efficacy, advise alternative contraception. - Phenytoin: may alter plasma concentrations, monitor seizure control. - Loop diuretics: monitor renal function and electrolytes.